DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring 12 lead ECG Telemetry Halter...

116
DYSRHYTMIAS & Hemodynamic Monitoring

Transcript of DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring 12 lead ECG Telemetry Halter...

Page 1: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

DYSRHYTMIAS& Hemodynamic Monitoring

Page 2: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Cardiac Rhythm Monitoring 12 lead ECG Telemetry Halter monitor Bedside monitor

Page 3: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Lead placement 12 lead

12 lead ECG

Diagnostic Structural

changes Ischemia Infarction Enlarged cardiac

chambers Electrolyte

imbalances Drug toxicity

Assessment of dysrhythmias

Page 4: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Lead placement 5 lead

5 lead monitoring

Telemetry monitoring ICU Holter monitors Provides more views

in different leads

Page 5: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Lead placement 3 lead Three Lead

Less lead views Simple monitoring Quick

Page 6: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Patch Considerations

Properly prepare skin Clip excessive hair on

the chest wall with scissors

Gently rub the skin with dry gauze

If skin is oily, wipe with alcohol first

Page 7: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Heart Anatomy& Conduction System

Page 8: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Conduction System

Page 9: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Properties of Cardiac Cells Automaticity

Ability to initiate an impulse spontaneously and continuously

Excitability

Ability to be electrically stimulated

Conductivity

Ability to transmit an impulse along membrane in an orderly

manner

Contractility

Ability to respond mechanically to an impulse

Page 10: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Nervous System Control of the Heart

Autonomic nervous system

controls: Rate of impulse formation Speed of conduction Strength of contraction

Page 11: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Nervous System Control of the Heart

Parasympathetic nervous system Vagus nerve Decreases rate Slows impulse conduction Decreases force of contraction

Page 12: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Nervous System Control of the Heart

Sympathetic nervous system Increases rate Increases force of contraction

Page 13: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Intrinsic Rates of the Conduction System

SA node 60-100

AV node 40-60

Bundle of His, Purkinje fibers 20-40

Ventricles <20

Page 14: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.
Page 15: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

P Wave Atrial depolarization Firing of SA node Should be upright

Normal duration 0.06-0.12 sec

Source of variation Disturbance in atria

Page 16: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

PR Interval

Impulse through atria to AV node, bundle of His

Measured from beginning of P wave to beginning of QRS complex

Normal duration 0.12-0.20 sec

Source of variation Short – impulse from AV

junction Longer – AV block

Page 17: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

QRS Interval Ventricular Depolarization Atrial repolarization

Hidden in wave Measured from the

beginning to end of QRS complex

Normal is not always a traditional wave form

Normal duration < 0.12 sec

Source of variation Disturbance in bundle

branches or in ventricles

Page 18: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

QRS variationsnot everyone has “normal” QRS

Page 19: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ST Segment

Time between ventricular depolarization and repolarization

Should be flat (isoelectric) Look for elevation or

depression ST elevation – myocardial

injury ST depression – reciprocal

changes and ischemia Normal duration

0.12 sec Source of variation

Ischemia Injury infarction

Page 20: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

T Wave

Ventricular repolarization Should be upright Follows QRS complex Larger than a P wave Inversion indicates ischemia

to myocardium Normal duration

0.16 sec Sources of variation

Electrolyte imbalances Ischemia Infarction

Page 21: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

QT Interval Beginning of QRS complex to

end of T wave Represents time taken for

entire ventricular depolarization and repolarization

Normal duration 0.34-0.43 sec

Sources of variation Drugs Electrolyte imbalances Changes in heart rate – inverse

relationship

Page 22: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

U Wave

Sometimes seen after T wave

?? May be normal May indicate hypokalemia

Page 23: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Rhythm interpretationA Systematic Approach

Page 24: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.
Page 25: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Rules for Systematic Interpretation

If the rhythm doesn’t look right check your patient! Treat the patient not the monitor

Is the rhythm regular or irregular – R to R, then P to P

What is the heart rate Can you identify P waves Can you identify QRS complexes & T waves What is the ratio of P waves to QRS complexes What is the PR interval Anything else you notice that shouldn’t be there

Page 26: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Calculating Heart RateRegular

Small blocks into 1500Large blocks into 300

Irregular = 6-second strip

Divide by 300 between waves

Page 27: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Rhythms Rhythms that originate in the

atria

Page 28: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Normal Sinus Rhythm

Follows normal conduction pattern Rate

60-100 P wave

Normal , one per QRS PR interval

Normal, consistent (0.12-0.20) QRS complex

Normal (<0.12)

Page 29: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Bradycardia

ECG characteristics Rhythm

Regular, slow Rate

<60 P wave

Normal, one per QRS PR interval

0.12-0.20, consistent QRS complex

Normal, <0.12

Page 30: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Bradycardia Clinical Associations

Normal in fit, athletic individuals Normal in sleep Increased vagal tone –e.g. vomiting Drugs

Beta blockers Calcium channel blockers

Hypothyroidism MI Increased intracranial pressure Hypoglycemia

Page 31: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Bradycardia Clinical significance

Dependent on patient tolerance Symptomatic

Pale Cool skin Hypotension Weakness Angina Dizziness Syncope Confusion or disorientation SOB

Page 32: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Bradycardia Treatment

Atropine Pacemaker Treat underlying cause

Page 33: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Tachycardia

ECG characteristics Rhythm

Regular, fast Rate

100-200 P wave

Normal, one for every QRS PR interval

0.12-0.20, consistent QRS complex

Normal, <0.12

Page 34: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Tachycardia Clinical Associations

Exercise Anxiety, pain, fear Hypotension Hyperthyroidism Hypovolemia Anemia Hypoxia Hypoglycemia MI Heart failure

Page 35: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Tachycardia

Clinical Associations (cont’d) Drugs

Epinephrine Norepinephrine Atropine Caffeine Theophylline Nifedipine Hydralazine Sudafed

Page 36: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Tachycardia Clinical significance

Dependent on tolerance Symptoms

Dizziness Dyspnea Hypotension Angina

Treatment Treat underlying cause Vagal maneuvers Beta blockers

Page 37: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Arrhythmia

ECG characteristics Rhythm

Irregular, but with a pattern Speeds up with respiration

Rate 60-100

P wave normal

PR interval normal

QRS complex normal

Page 38: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Sinus Arrhythmia Clinical Associations Clinical significance Treatment

Page 39: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Fibrillation

ECG characteristics Rhythm

irregular Rate

Atrial 350-600, irregular Ventricular - < & > 100 – irregular

P wave Irregular, chaotic

PR interval Not measurable

QRS complex normal

Page 40: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Fibrillation Clinical Associations

CAD Rheumatic heart disease cardiomyopathy Hypertensive heart disease Heart failure Pericarditis Thyrotoxicosis Alcohol intoxication Caffeine Electrolyte disturbances Stress Cardiac surgery

Page 41: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Fibrillation Clinical significance

Most common, clinically significant dysrhythmia Decreased cardiac output Thrombus formation Stroke

Accounts for as many as 20% of all strokes Treatment

Calcium channel blockers Beta blockers Digoxin Amiodarone Cardioversion Anticoagulation therapy

Page 42: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Flutter

ECG characteristics Rhythm

May be regular or irregular Rate

Atrial – 200-350 and regular Ventricular - < & > 100 – regular or irregular

P wave Flutter waves – sawtoothed More than QRS complexes – may be in a ratio

PR interval Not measurable

QRS complex Normal

Page 43: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Flutter Clinical Associations

CAD HTN Mitral valve disorders PE’s Chronic lung disease Cor pulmonale Cardiomyopathy Hyperthyroidism Digoxin Quinidine Epinephrine

Page 44: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Atrial Flutter Clinical significance

Decrease cardiac output Heart failure Increased risk of stroke

Treatment Slow ventricular response by increasing AV

block Calcium channel blockers Beta blockers Cardioversion Amiodarone Rhythmol Ablation

Page 45: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Supraventricular Tachycardia

ECG characteristics Rhythm

Regular Rate

150-220 P wave

Difficult to determine – may be hidden Abnormal

PR interval Normal or shortened

QRS complex Normal

Page 46: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Supraventricular Tachycardia Clinical Associations

Overexertion Emotional stress Deep inspiration Caffeine Tobacco Rheumatic heart disease Digitalis toxicity CAD Cor pulmonale

Page 47: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Supraventricular Tachycardia Clinical significance

Prolonged episodes may precipitate decreased cardiac output

Symptoms Hypotension Dyspnea Angina

Treatment Vagal stimulation

Valsalva maneuver Drugs

Adenosine Beta blockers Calcium channel blockers

Cardioversion

Page 48: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Asystole

There is no electrical activity in the heart during asystole, therefore there will only be a flat line on the rhythm strip

Page 49: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Asystole Clinical Associations

Advanced cardiac disease Severe cardiac conduction system disturbance End stage heart failure

Clinical significance Prolonged arrest, may not be resuscitated

Treatment CPR with ACLS Epinephrine Atropine Intubation Transcutaneous temporary pacemaker

Page 50: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Beats

Page 51: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Atrial Contractions (PAC’s)

Beats occur early in the cycle and there is no compensatory pause ECG characteristics

Rhythm irregular

Rate Dependent on underlying rhythm

P wave Abnormal shape

PR interval Normal Will be different than underlying rhythm

QRS complex Normal

Page 52: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Atrial Contractions (PAC’s) Clinical Associations

Can occur normally Emotional stress Physical fatigue Alcohol Caffeine Tobacco CHF Ischemia COPD Hypoxia Hyperthyroidism CAD

Page 53: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Atrial Contractions (PAC’s)

Clinical significance In healthy hearts, not significant Symptoms

Heart “skipped” beat Palpitations

May be early indication of more serious dysrhythmias

Treatment Reduce stimulants Beta blockers

Page 54: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Ventricular Contractions (PVC’s)

Beat early in cycle with compensatory pause ECG characteristics

Rhythm irregular

Rate Dependent on underlying rhythm

P wave No P wave with premature beat

PR interval none

QRS complex Wide bizarre, >0.12

Page 55: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Ventricular Contractions (PVC’s) Bigeminy

Every other beat is a PVC Trigeminy

Every third beat is a PVC Unifocal

All PVC’s from same source Look alike

Multifocal Different sources of beat Beats look different

Couplet Two in a row Runs will turn into V-tach

Page 56: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Ventricular Contractions (PVC’s)

Clinical Associations Caffeine Alcohol Nicotine Aminophylline Epinephrine Digoxin Electrolyte imbalances Hypoxia Fever Exercise Emotional stress MI Mitral valve prolapse Heart failure CAD

Page 57: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Ventricular Contractions (PVC’s) Clinical significance

Usually benign May precipitate

Decreased cardiac output Angina Heart failure

Assess apical-radial pulse rate Treatment

Treat underlying cause Beta blockers Procainamide Amiodarone Lidocaine

Page 58: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Junctional Contractions (PJC’s)

Beat occurs early in cycle and no compensatory pause ECG characteristics

Rhythm Irregular

Rate Dependent on underlying rhythm

P wave May or may not be present – if present will be inverted

PR interval Different from underlying rhythm if there at all

QRS complex normal

Page 59: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Premature Junctional Contractions (PJC’s) Clinical significance &Treatment

Similar to PAC’s

Page 60: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Junctional Rhythms Originate below atria and above

ventricles

Page 61: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Junctional Rhythm

ECG characteristics Rhythm

regular Rate

40-60 P wave

Inverted, may be hidden in QRS complex PR interval

Shortened or missing QRS complex

normal

Page 62: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Accelerated Junctional Rhythm & Junctional Tachycardia

ECG characteristics Rhythm

regular Rate

60-180 P wave

Inverted, may be hidden in QRS complex PR interval

Shortened or missing QRS complex

normal

Page 63: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Junctional Dysrhythmias Clinical Associations

CAD Heart failure Cardiomyopathy Electrolyte imbalances Inferior MI Rheumatic heart disease Digoxin Amphetamines Caffeine Nicotine

Page 64: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Junctional Dysrhythmias Clinical significance

Occur when the SA node has not been effective

If increases to junctional tachycardia patient may become hemodynamically unstable

Treatment Dependent on tolerance Atropine Beta blockers Calcium channel blockers Amiodarone

Page 65: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Rhythms Originate in the ventricles

Page 66: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Idioventricular Rhythm

ECG characteristics Rhythm

Regular Rate

20-40 P wave

none PR interval

absent QRS complex

Wide, bizarre >0.20

Page 67: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Tachycardia

ECG characteristics Rhythm

Regular R to R Rate

Ventricular rate 150-250 P wave

none PR interval

none QRS complex

Wide, bizarre, > 0.12

Page 68: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Tachycardia Run of three or more PVC’s Clinical Associations

MI CAD Significant electrolyte imbalances Cardiomyopathy Mitral valve prolapse Long QT syndrome Drug toxicity CNS disorders

Page 69: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Tachycardia Clinical significance

Stable – patient has a pulse Unstable – no pulse Decreased cardiac output Hypotension Pulmonary edema Decreased cerebral blood flow Cardio-pulmonary arrest

Page 70: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Tachycardia Treatment

Treat quickly Identify and treat underlying causes Procainamide Sotalol Amiodarone Lidocaine Beta blockers Magnesium Dilantin Cardioversion CPR & ACLS

Page 71: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Fibrillation

ECG characteristics Rhythm

No rhythm present Rate

No rate P wave

No P waves PR interval

none QRS complex

none

Page 72: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Fibrillation Clinical associations

Acute MI Myocardial ischemia Heart failure Cardiomyopathy Cardiac catheterization Cardiac pacing Accidental electric shock Hyperkalemia Hypoxemia Acidosis Drug toxicity

Page 73: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Fibrillation Clinical significance

Symptoms Unresponsive Pulseless Apneic state

If not treated rapidly, patient will die Treatment

Immediate CPR & ACLS Immediate defibrillation

Page 74: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Ventricular Standstill

ECG characteristics Rhythm

Regular p waves Rate

Atria 60-80 P wave

normal PR interval

none QRS complex

none

Page 75: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Heart Blocks

Page 76: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

First Degree AV Block

ECG characteristics Rhythm

Regular Rate

Normal P wave

Normal PR interval

>0.20 QRS complex

normal

Page 77: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

First Degree AV Block Clinical Association

MI CAD Rheumatic fever Hyperthyroidism Vagal stimulation Digoxin Beta blockers Calcium channel blockers

Page 78: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

First Degree AV Block Clinical significance

Usually not serious Can be a precursor for higher degrees of AV

block Patients are asymptomatic

Treatment No treatment unless caused by medications Monitor patient for increase in block

Page 79: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Second Degree AV Block – Type I

Also called Mobitz I or Wenckebach ECG characteristics

Rhythm Irregular

Rate Atrial – normal and regular Ventricular – slightly higher than atrial rate

P wave More p waves than QRS complexes

PR interval Progressing lengths until drops QRS

QRS complex Normal and then one dropped

Page 80: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Second Degree AV Block – Type I Clinical Association

Digoxin Beta blockers CAD

Clinical significance Myocardial ischemia or infarction Generally transient and well tolerate May be warning sign for a more serious AV

disturbance Treatment

Symptomatic Atropine Temporary pacemaker

Asymptomatic Closely monitored Transcutaneous pacer on standby

Page 81: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Second Degree AV Block – Type II

Also called Mobitz II ECG characteristics

Rhythm Irregular Regular if consistent conduction ratio

Rate Atrial – normal and regular Ventricular – slower, regular or irregular

P wave More p waves than QRS complexes, stated in a ratio

PR interval Normal or prolonged

QRS complex Preceded by two or more P waves

Page 82: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Second Degree AV Block – Type II Clinical Association

Rheumatic heart disease CAD Anterior MI Drug toxicity

Clinical significance Often progresses to third degree AV block Poor prognosis Decreased cardiac output Hypotension Myocardial ischemia

Treatment Permanent pacemaker

Page 83: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Third Degree AV Block

ECG characteristics Rhythm

R-R regular P-P regular

Rate Atrial 60-100 Ventricular 20-60, dependent on focus

P wave Normal, more P waves than QRS complexes

PR interval No relationship between P waves and QRS complexes

QRS complex Dependent on focus

Page 84: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Third Degree AV Block Clinical Association

Severe heart disease CAD MI Myocarditis Cardiomyopathy

Amyloidosis Scleroderma Digoxin Beta blockers Calcium channel blockers

Page 85: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Third Degree AV Block Clinical significance

Reduced cardiac output Ischemia Heart failure Shock Syncope possible periods of asystole

Treatment Pacemaker Atropine Epinephrine Dopamine Calcium chloride

Page 86: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Bundle Branch Blocks

ECG characteristics QRS complex

Wide, bizarre

Page 87: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Bundle Branch Blocks Clinical significance Treatment

Page 89: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation & Cardioversion

Including pacemakers and implanted cardioverter defibrillator

Page 90: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Lifepak

Can be used as defibrillator, monitor, or transcutaneous pacer

Page 91: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation The use of a carefully controlled electric shock,

administered either through a device on the exterior of the chest wall or directly to the exposed heart muscle, to restart or normalize heart rhythms.

Most effective method of terminating V-Fib and pulseless V-Tach

Deliver energy using a monophasic or biphasic waveform Monophasic defibrillators deliver energy in one

direction. Biphasic defibrillators deliver energy in two

directions. Deliver successful shocks at lower energiesFewer post shock ECG abnormalities

Page 92: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation Output is measured in joules or watts

per second. Recommended energy for initial shocks

in defibrillation Biphasic defibrillators: First and

successive shocks: 150 to 200 joules Monophasic defibrillators: Initial shock at

360 joules

Page 93: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation

Indications Pulseless v-tach V-fib Always done as emergent

Contraindications Multifocal atrial tachycardia Digitalis toxicity

Page 94: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Cardioversion Restoration of normal heart rhythm: the

use of an electric shock to convert a dangerously rapid, fluttering, and ineffective heartbeat to its normal rhythm Synchronized circuit delivers a counter

shock on the R wave of the QRS Synchronizer switch must be turned

ON

Page 95: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Cardioversion Indications

A-fib If unstable or new witnessed onset – may do

without anticoagulation but preferred method is with anticoagulation three weeks prior

TEE to rule out blood clots A-flutter (if unstable)

Anticoagulation therapy Stable V-tach (with pulse)

If patient does not respond to medications Contraindications

Digitalis toxicity associated tachycardia

Page 96: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation & Cardioversion Nursing Considerations

IV access Airway management equipment Sedative drugs Monitor Be aware of possible implanted devices Firm pressure when discharging

Decrease chance for arcing and burns Clear of patient and bed

Page 97: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Defibrillation & Cardioversion Complications

Hypoxia or hypoventilation from sedation Burns

Mostly superficial some deep tissue Dysrhythmias

Premature beats V-fib

Hypotension Pulmonary edema Thromboembolization Myocardial necrosis r/t high energy discharge

Page 98: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ICD’s & Pacemakers

Page 99: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Implantable Cardioverter- Defibrillators (ICD’s)

A, The implantable cardioverter-defibrillator (ICD) pulse generator from Medtronic, Inc.B, The ICD is placed in a subcutaneous pocket over the pectoralis muscle. A single-lead system is placed transvenously from the pulse generator to the endocardium. The single lead detects dysrhythmias and delivers an electric shock to the heart muscle.

Page 100: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Indications for ICD

Spontaneous sustained v-tach Syncope with inducible v-tach/v-fib

during EP study At high risk for future life-threatening

dysrhythmias (cardiomyopathy) Have survived cardiac arrest

Page 101: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ICD’s Consists of a lead system placed via

subclavian vein to the endocardium Battery-powered pulse generator is

implanted subcutaneously ICD sensing system monitors the HR and

rhythm and identifies VT or VF.

Approximately 25 seconds after detecting VT or VF, ICD delivers <25 joules.

If first shock is unsuccessful, ICD recycles and delivers successive shocks

Page 102: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ICD’S ICDs are equipped with anti-tachycardia

and anti-bradycardia pacemakers. Initiate overdrive pacing of

supraventricular and ventricular tachycardias

Provide backup pacing for brady dysrhythmias that may occur after defibrillation discharges

Education is extremely important Participation in an ICD support group

should be encouraged

Page 103: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

A, A dual-chamber rate-responsive pacemaker from Medtronic, Inc., is designed to treat patients with chronic heart problems in which the heart beats too slowly to adequately support the body's circulation needs.B, Pacing leads in both the atrium and ventricle enable a dual-chamber pacemaker to sense and pace in both heart chambers.

Pacemakers

Page 104: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Pacemakers Used to pace the heart when the normal

conduction pathway is damaged or diseased Pacing circuit consists of a power source,

one or more conducting (pacing) leads, and the myocardium

Page 105: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Pacemaker types Permanent

Single chamber Dual chamber

Temporary Transcutaneous Transvenous epicardial

Page 106: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Indications for permanent pacemakers

Page 107: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Indications for a temporary pacemaker

Page 108: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Pacemakers Anti-bradycardia pacing Anti-tachycardia pacing: Delivery of a

stimulus to the ventricle to terminate tachy-dysrhythmias

Overdrive pacing: Pacing the atrium at rates of 200 to 500 impulses per minute to terminate atrial tachycardias

Permanent pacemaker: Implanted totally within the body

Cardiac resynchronization therapy (CRT): Pacing technique that resynchronizes the cardiac cycle by pacing both ventricles

Page 109: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

Temporary pacemakers Temporary pacemaker: Power source

outside the body Transvenous

Leads threaded through veins to right atrium or ventricle

Epicardial Placed during cardiac surgery – leads are

passed through the chest wall and can be attached to an external power source

Transcutaneous Placed one lead on top of chest and one lead

posterior

Page 110: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ICD’s & Pacemakers Complications

Infection Hematoma formation at sites of insertion Pneumothorax Failure to sense or capture Perforation of atrial or ventricular septum

by the pacing lead Corrosion of leads Battery depletion

Page 111: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG Changes Associated with ACS

Page 112: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG changes in ACS Ischemia

ST segment depression and/or T wave inversion

ST segment depression is significant if it is at least 1 mm (one small box) below the isoelectric line.

Page 113: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG changes in ACS

Changes occur in response to the electrical disturbance in myocardial cells due to inadequate supply of oxygen.

Once treated (adequate blood flow is restored), ECG changes resolve and ECG returns to baseline

Page 114: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG changes in ACS Injury

ST segment elevation is significant if >1 mm above the isoelectric line. If treatment is prompt and effective, may avoid

infarction If serum cardiac markers are present, an ST-segment-

elevation myocardial infarction (STEMI) has occurred.

Page 115: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG changes in ACS Infarction

Physiologic Q wave is the first negative deflection following the P wave. Small and narrow (<0.04 second in

duration) Pathologic Q wave is deep and >0.03

second in duration

Page 116: DYSRHYTMIAS & Hemodynamic Monitoring. Cardiac Rhythm Monitoring  12 lead ECG  Telemetry  Halter monitor  Bedside monitor.

ECG changes in ACS Infarction

Pathologic Q wave indicates that at least half the thickness of the heart wall is involved. Referred to as a Q wave MI Pathologic Q wave may be present

indefinitely. T wave inversion related to infarction

occurs within hours and may persist for months